Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 541 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Importance of achieving the composite endpoints in diabetes

Unnikrishnan Ambika Gopalakrishnan, Bhattacharyya Arpandev, Baruah Manash Pratim, Sinha Binayak, Dharmalingam Mala, Rao Paturi V

Year : 2013| Volume: 17| Issue : 5 | Page no: 835-843

   This article has been cited by
1 Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis
Xinhua Xiao,Changjiang Wang,Xiaoyang Lai,Bin Zhang,Liqun Gu,Jianing Hou,Zhiguang Zhou
Journal of Diabetes Investigation. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Impact of medication nonadherence on stroke recurrence and mortality in patients after first-ever ischemic stroke: Insights from registry data in Singapore
See-Hwee Yeo,Matthias Paul Han Sim Toh,Sze Haur Lee,Raymond Chee Seong Seet,Lai Yin Wong,Wai-Ping Yau
Pharmacoepidemiology and Drug Safety. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Yoga-based lifestyle treatment and composite treatment goals in Type 2 Diabetes in a rural South Indian setup- a retrospective study
Geetharani Arumugam,Raghuram Nagarathna,Vijaya Majumdar,Mandeep Singh,Rambabu Srinivasalu,Rajagopal Sanjival,Venkat S. Ram,Hongasandra Ramarao Nagendra
Scientific Reports. 2020; 10(1)
[Pubmed]  [Google Scholar] [DOI]
4 Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
Ayako Fuchigami,Fumika Shigiyama,Toru Kitazawa,Yosuke Okada,Takamasa Ichijo,Mariko Higa,Toru Hiyoshi,Ikuo Inoue,Kaoru Iso,Hidenori Yoshii,Takahisa Hirose,Naoki Kumashiro
Cardiovascular Diabetology. 2020; 19(1)
[Pubmed]  [Google Scholar] [DOI]
5 Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
Fumika Shigiyama,Naoki Kumashiro,Ayako Fuchigami,Takahisa Hirose
Cardiovascular Diabetology. 2018; 17(1)
[Pubmed]  [Google Scholar] [DOI]
6 Simultaneous inference of a binary composite endpoint and its components
M. Große Ruse,C. Ritz,L.A. Hothorn
Journal of Biopharmaceutical Statistics. 2016;
[Pubmed]  [Google Scholar] [DOI]
7 Proceedings From FDA/A.S.P.E.N. Public Workshop
Daniel H. Teitelbaum,Peggi Guenter,Donna Griebel,Steven A. Abrams,Staffan Bark,Mary Baker,Karyn L. Berry,Bruce R. Bistrian,J. Thomas Brenna,Denis Bonnot,Yvon A. Carpentier,Richard J. Deckelbaum,Mary Hise,Berthold Koletzko,Jay M. Mirtallo,Andrew E. Mulberg,Randall C. O’Reilly,Jonathan Shaffer,Elke von Kleist,Gary P. Zaloga,Thomas R. Ziegler
Journal of Parenteral and Enteral Nutrition. 2015; 39(7): 768
[Pubmed]  [Google Scholar] [DOI]
8 A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes
Stuart A. Ross
Current Medical Research and Opinion. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]


Read this article